SynBiotic Logo
DE000A3E5A59
A3E5A5
SBX.DE

SynBiotic

A carregar cotações...

Previsão

Não temos dados de analistas para esta empresa.


  • SYNBIOTIC SE: subsidiary Hempro International applies for preliminary insolvency proceedings

    Management of Hempro International has announced it will file an application with the Münster district court to open preliminary insolvency proceedings. The causes are a marked drop in demand and sales since March 2026 due to worsening economic conditions following geopolitical events. SYNBIOTIC SE is reconsidering the operational development of its subsidiaries as part of restructuring measures and will no longer continue financial support for Hempro; potential impacts on the balance sheet and results are being reviewed. » Mais em finanzen.net


  • SynBiotic share plunges almost 20% after US cannabis reclassification

    The SynBiotic share lost 14.4% in Xetra trading and fell a further almost 20% in after-hours trading. The trigger was the official initiation of a US reclassification of cannabis intended to make medical use easier but not to provide nationwide legalization for recreational purposes. Ahead of this, the stock had already benefited from speculation about a loosening of US rules. » Mais em finanzen.net


  • Synbiotic shares more than double since Friday after anchor investor steps in

    Synbiotic shares rose by more than 100% since Friday and continued on Wednesday with a gain of over 12% to 3.55 euros; intraday they reached up to 3.78 euros. Earlier in the week the papers had already climbed by as much as 42% after they had marked a record low near 1.50 euros last week. Analyst Harald Hof cited several positive triggers: two smaller capital increases, the insolvency of a non-core subsidiary, sector tailwinds and the entry of the hemp equity fund Cansoul as a new anchor investor in a cash capital increase. » Mais em de.investing.com

Em 2022, SynBiotic já distribuiu € 0,30 em dividendos. A última distribuição ocorreu em julho de 2022.

Dados financeiros da empresa

No último ano, SynBiotic registou receitas de € 3,86 mi e um ganho líquido de -€ 10,63 mi
(EUR) 2023
YoY
Receitas 3,86 mi 52,71%
Ganho bruto 1,51 mi 57,83%
Ganho líquido -10,63 mi 56,36%
EBITDA -7,12 mi 4,85%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 4,84 mi
Número de ações
4,75 mi
Máximo/mínimo de 52 semanas
€ 3,85 - € 0,50
Dividendos Não
Beta
0,68
PER (PE Ratio)
-0,46
PEG (PEG Ratio)
0,00
P/VC (PB Ratio)
0,31
P/V (PS Ratio)
1,25

Perfil da empresa

SynBiotic SE beschäftigt sich mit der Entwicklung von Medikamenten und rezeptfreien Wellness-Produkten auf der Basis von Cannabinoiden. Das Unternehmen konzentriert sich auf die synthetische Herstellung von Cannabinoiden, die Entwicklung von Medikamenten, Nahrungsergänzungsmitteln und kosmetischen Produkten. Das Unternehmen war früher als Ledgertech SE bekannt und änderte seinen Namen in Ledgertech SE. SynBiotic SE hat seinen Sitz in München, Deutschland.

Nome
SynBiotic
CEO
Daniel Kruse
Sede Düsseldorf, nw
Alemanha
Site
Setor
Cuidados de saúde
Indústria
Biotecnologia
Entrada em bolsa
07/01/2021
Colaboradores 79

Símbolos de ticker

Bolsa Símbolo
XETRA
SBX.DE
Frankfurt
SBX.F
Düsseldorf
SBX.DU
Hamburg
SBX.HM
München
SBX.MU
SIX
SBX.SW
🍪

Parqet  utiliza cookies. Saber mais